The primary goal of mammography screening is to decrease mortality in patients with breast cancer. the aim of the study was evaluation of the screening program results on course of implemented therapy and its results in breast carcinoma patients. material and methods. Evidence includes data on the group of 1818 patients with breast cancer that were subject to surgical treatment at the Clinic of Breast Cancer and Reconstructive Surgery of the Oncology Center in Bydgoszcz (558 patients hospitalized from
mon also in Poland) population programs of prevention and early diagnosis of neoplastic diseases.
The supreme goal of mammographic screening is reduction of patient mortality due to breast cancer. Studies conducted by Jacson et al. (2) and Spillane et al. (3) demonstrated that in a population of women over 50 years oldwho took part in screening programs there was an approx. 30-32% decrease in the risk of death caused by malignant neoplasms of the mammary gland. In addition, prevention programs allow implementation of treatment sparing the mammary gland (breast-conserving treatment, BCT) or the axillary lymphatic system (sentinel lymph node biopsy, SLNB) in a greater percentage of patients (2, 3, 4) . As a result, surgical treatment of patients with early-stage breast cancer can be less mutilating and associated with a smaller risk of serious complications.
Detection of neoplastic changes in the breast using mammography (MMG), as part of preventive examinations, makes it often possible to establish a diagnosis and start the treatment at an early, asymptomatic stage of the disease (5) . This has significant clinical meaning. 5-year survival of patients with stage I breast cancer is possible in 90% of cases, while in patients with stage III disease -only in approx. 40% of cases (5) .
The present study evaluates the results of using mammographic screening and its impact on treatment options available for breast cancer patients, based on our oncology center's own experience. In both groups of patients, the objects of assessment and comparison included the type of preoperative diagnosis of the disease, stage of clinical progression and results of pathological evaluation of preparations. The analysis included also the types of surgical procedures performed, proportion of preoperative systemic treatment as well as indications for the procedures.
MATERIAL AND METHODS
In addition, irrespective of the treatment period, two groups were established: the screening group (patients with a tumor detected in MMG screening) and the symptomatic group (cases of cancer diagnosed outside of the screening program), which were also an object of comparative assessment.
In case of patients undergoing BCT and/or SLNB, qualification for these procedures was carried out in accordance with recommendations of the Polish Union of Oncology (Polska Unia Onkologii) (6) (in 2006, diagnosis of comedo component was considered an additional indication for mastectomy; later it was decided otherwise).
Differences between the study groups were assessed using a two-proportion parametric test based on normal distribution statistics. Differences between compared groups of data were considered statistically significant at p < 0.05.
RESULTS
The analyzed group of patients consisted of 1814 women and 4 men, aged between 23 and 90 (mean patient age in the first period of evaluation was 56.4 years, and 57.8 years in the years 2011-2012). The mean patient age in the screening group was 58.8 years (in 2006) and 59.9 (in the years 2011-2012), and among the remaining patients it was 55.9 and 56.4 years, respectively (p > 0.05).
In 2006, in 28.4% of the analyzed patients (within the age limit specified in the program) a primary tumor was detected using screening examinations. In the following years of observation, mammographic screening allowed diagnosis in 61.5% of cases (in 508 of 826 patients aged between 50 and 69;p < 0.05).
In the first period of evaluation, 35.7% of operated tumors did not exceed 2 cm in size -cT1 (compared with 48.3% in the years 2011-2012, a statistically significant difference). At the same time, the percentage of cT4 tumors was 9.9% (versus 4.7% in the later period, which was also a statistically significant difference). Detailed data on distribution of primary tumor sizes in the two periods of evaluation as well as information concerning patients of the screening and symptomatic groups are presented in tab. 1 (in case of 8 patients treated in 2006, no information was obtained about the mode of performing preoperative MMG).
In the analyzed clinical material, in 10.4% (2006) In addition, the number of DCIS cases was established. In 2006, the overall proportion of patients with DCIS was 2.7% (2.2% in the screening group and 2.8% in the symptomatic group), and in the later period -3.5%, with equal proportions in both subgroups. The two evaluated periods were characterized by different proportions of patients undergoing breast-conserving treatment (detailed data are presented in tab. 3). In patients treated in the years 2011-2012, statistically significant differences were detected in the numbers of patients undergoing BCT and ACT in the screening and symptomatic groups, which was not the case in patients treated in 2006.
In were not statistically significant. In both evaluated periods, this therapy was used 2.5 to 3 times more frequently in the symptomatic group.
DISCUSSION
Our studies revealed statistically significant differences in the size of primary tumors BCT -breast conserving treatment, SLNB -sentinel lymph node biopsy, ACT -axillary conserving treatment Unauthenticated Download Date | 6/21/17 2:03 PM and the degree of axillary lymph node involvement, especially when patients from the screening and symptomatic groups were compared.
As Australian experiences show (3), the BreastScreen Australia program introduced in 1991 allowed participants to be diagnosed with statistically significantly smaller tumors compared with patients in the symptomatic group (18.1 vs 22.1 mm; p < 0.001). Analogous differences were seen in the proportion of axillary metastases (28% vs 41%; p = 0.003) and invasive tumors of diameter less than 15 mm (58% vs 33%; p < 0.001).
One of characteristic changes resulting from introduction of common screening examinations is a significant increase in the number of diagnosed breast cancer cases of the DCIS type. According to Silverstein (7) and other authors (8, 9) , the percentage of DCIS cases among all neoplastic changes of the breast increased from 2-5% (the period before screening examinations were performed) to 20-30% after screening examinations became common.
The small percentage of cases of ductal carcinoma in situ in our study does not confirm the above results, but this requires further analysis.
In a summary of a 20-year period of performing breast cancer screening, Esserman et al. (10) noted that the observed increase in proportion of diagnosed early-stage tumors stopped being accompanied by a decrease in the total number of advanced cases, which was seen directly after screening was introduced. The problem of overdetection of tumors with a low risk of treatment failure, especially of DCIS cases with a low degree of malignancy, is confirmed also by Welch and Black (11). Thus, the authors suggest that in order to achieve further decrease in mortality due to this type of cancer, it is necessary to change the approach towards the screening program (12) .
Our former experiences with MMG screening showed both a statistically significant increase in patients with stage I disease (overall change from 30.8% in 2006 to 44.2% in the years 2011-2012) and a similar decrease in the proportion of more advanced cases. This indicates a relatively early stage of implementation of screening examinations in Poland.
Observed differences between the evaluated periods as regards the proportion of patients undergoing breast-conserving treatment resulted from failure to apply the same contraindications to BCT (comedocarcinoma). That is why only the results obtained in the later period can be used in a proper assessment. In the years 2011-2012, BCT was performed in nearly half patients undergoing surgical treatment, with a statistically significant difference between the screening (63.0%) and symptomatic (41%) groups. The difference was even more prominent in case of treatment aimed at conservation of the axillary lymphatic system -75.4% vs. 53.1% (2011-2012; the SLNB procedure was not routinely used in 2006).
According to Spillane et al. (3), the desired proportion of BCT in patients diagnosed during mammographic screening was 70%, while in the remaining patients -50%. Conclusions reached in an analysis performed by the authors come from a period when the use of breast cancer screening was more advanced (it was performed in 54% women within the age limit specified in the program). Further continuation of our studies may lead to achieving such proportions.
Data published by Smith et al. (13) and Humphrey et al. (14) indicate that sufficiently early detection of cancer -mainly possible because of the use of MMG screening -makes it possible to avoid mastectomy in more than 60% of surgically treated patients.
However, according to Dixon (15) , common use of screening examinations may paradoxically lead to an increase in number of mastectomies. The author stated that the reason of this, which was also suggested by other authors (2, 3, 10, 11) , is an increase in detectability of DCIS-type tumors, especially those larger than 4 cm, and multifocal tumors.
In both evaluated periods, no statistically significant difference was seen regarding the proportion of patients requiring initial systemic treatment and indications for initiating such treatment. Among cases of patients undergoing induction (or neoadjuvant) treatment, the biggest group comprised patients with stage III disease, that is approx. 75-80% of all patients treated this way. At the same time, in both evaluated periods, the option of preoperative systemic treatment was used only in 1 of 10 patients with cT2N1 or cT3N0 tumors (stage IIB).
According to current guidelines, the use of preoperative chemotherapy is indicated also in patients with primary operable breast tumors (16, 17, 18) . This is true especially in cases where the need for adjuvant treatment is expected, as well as in patients with preliminary disqualification from BCT.
CONCLUSIONS
There were statistically significant differences between the two analyzed periods as regards the extent of the breast cancer early detection program as well as the stage of clinical and pathological progression of the diagnosed neoplastic disease.
The increase in the use of screening examinations observed in breast cancer patients resulted in statistically significantly more frequent use of breast-conserving surgical procedures. In further consequence of these changes, one might expect an improvement in distant outcomes of treatment, including lower mortality due to breast cancer. This requires continuation of the ongoing studies.
